Proactive Investors - Run By Investors For Investors

Rhinomed Limited to update on first stage of global pharmacy distribution

Rhinomed Limited to update on first stage of global pharmacy distribution

Rhinomed Limited (ASX:RNO) has been granted an ASX trading halt in relation to the first stage in global pharmacy distribution.

The halt will last until the earlier of the announcement being made or the start of trade on Friday, 21st August 2015.

In the June 2015 Quarter, the company reported receipts from customers of $192,000, an increase of $33,000 from the previous quarter due to growing demand for its Turbine sports breathing device.

Sales in FY2016 are expected to increase due to expanded global distribution of Turbine. It has also received early demand for its Mute snoring and sleep technology.

Rhinomed had $1.37 million in cash as at 30th June 2015.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full RNO profile View Profile

Rhinomed Ltd Timeline

September 15 2015

Related Articles

June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
man with erectile dysfunction
April 26 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use